VX-702

• UNSPSC Description:

  VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β[1].

• Target Antigen:

  Autophagy; p38 MAPK

• Type:

  Reference compound

• Related Pathways:

  Autophagy;MAPK/ERK Pathway

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/VX-702.html

• Purity:

  99.54

• Solubility:

  DMSO : ≥ 42 mg/mL

• Smiles:

  O=C(N)C1=CC=C(N=C1C2=CC=C(C=C2F)F)N(C3=C(C=CC=C3F)F)C(N)=O

• Molecular Weight:

  404.32

• References & Citations:

  [1]Kuliopulos A, et al. Effect of selective inhibition of the p38 MAP kinase pathway on platelet aggregation. Thromb Haemost, 2004, 92(6), 1387-1393.|[2]Braddock M, IDDB Meeting Report, 2005, March 14-15.|[3]Gill A, IDDB Meeing Report, 2002, March 06-08.|[4]Naka K, et al. Dipeptide species regulate p38MAPK-Smad3 signalling to maintain chronic myelogenous leukaemia stem cells. Nat Commun. 2015 Aug 20;6:8039.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Phase 2

• CAS Number:

  745833-23-2